Andreas Argyrides
Stock Analyst at Oppenheimer
(4.39)
# 356
Out of 5,182 analysts
124
Total ratings
53.7%
Success rate
19.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRD Opus Genetics | Initiates: Outperform | $10 | $5.12 | +95.31% | 1 | Mar 16, 2026 | |
| LQDA Liquidia | Maintains: Underperform | $16 → $19 | $37.34 | -49.12% | 8 | Mar 12, 2026 | |
| GOSS Gossamer Bio | Maintains: Outperform | $12 → $3 | $0.35 | +760.83% | 9 | Mar 5, 2026 | |
| UTHR United Therapeutics | Maintains: Outperform | $575 → $600 | $566.99 | +5.82% | 2 | Feb 26, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Outperform | $30 → $35 | $16.85 | +107.72% | 15 | Feb 24, 2026 | |
| EVMN Evommune | Initiates: Outperform | $42 | $25.00 | +68.00% | 1 | Jan 22, 2026 | |
| DYN Dyne Therapeutics | Upgrades: Outperform | $11 → $40 | $18.04 | +121.73% | 5 | Dec 10, 2025 | |
| SVRA Savara | Maintains: Outperform | $8 → $9 | $5.16 | +74.42% | 2 | Nov 14, 2025 | |
| KROS Keros Therapeutics | Reiterates: Outperform | $23 → $27 | $11.01 | +145.23% | 9 | Nov 12, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Outperform | $77 → $115 | $54.02 | +112.88% | 2 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $21 | $4.44 | +372.97% | 2 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $29 | $12.61 | +129.98% | 2 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $33 | $0.12 | +27,538.19% | 2 | Sep 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $2.63 | +470.34% | 2 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $20 | $5.34 | +274.53% | 2 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $61 | $31.05 | +96.46% | 1 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 → $7 | $4.10 | +70.73% | 5 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $3 | $1.61 | +86.34% | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $4 | $0.89 | +349.49% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $155 → $90 | $12.84 | +600.93% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $9 | $1.49 | +504.03% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $181 | $226.66 | -20.14% | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $7.95 | +138.99% | 9 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $27.11 | +6.97% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $21 | $8.62 | +143.62% | 4 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $224 | $20.98 | +967.68% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $25.55 | +123.09% | 2 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $70 | $9.98 | +601.40% | 3 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $0.21 | +4,661.90% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $70 | $53.81 | +30.10% | 6 | Aug 1, 2023 |
Opus Genetics
Mar 16, 2026
Initiates: Outperform
Price Target: $10
Current: $5.12
Upside: +95.31%
Liquidia
Mar 12, 2026
Maintains: Underperform
Price Target: $16 → $19
Current: $37.34
Upside: -49.12%
Gossamer Bio
Mar 5, 2026
Maintains: Outperform
Price Target: $12 → $3
Current: $0.35
Upside: +760.83%
United Therapeutics
Feb 26, 2026
Maintains: Outperform
Price Target: $575 → $600
Current: $566.99
Upside: +5.82%
MoonLake Immunotherapeutics
Feb 24, 2026
Maintains: Outperform
Price Target: $30 → $35
Current: $16.85
Upside: +107.72%
Evommune
Jan 22, 2026
Initiates: Outperform
Price Target: $42
Current: $25.00
Upside: +68.00%
Dyne Therapeutics
Dec 10, 2025
Upgrades: Outperform
Price Target: $11 → $40
Current: $18.04
Upside: +121.73%
Savara
Nov 14, 2025
Maintains: Outperform
Price Target: $8 → $9
Current: $5.16
Upside: +74.42%
Keros Therapeutics
Nov 12, 2025
Reiterates: Outperform
Price Target: $23 → $27
Current: $11.01
Upside: +145.23%
Monopar Therapeutics
Oct 2, 2025
Maintains: Outperform
Price Target: $77 → $115
Current: $54.02
Upside: +112.88%
Oct 2, 2025
Maintains: Outperform
Price Target: $26 → $21
Current: $4.44
Upside: +372.97%
Sep 16, 2025
Maintains: Outperform
Price Target: $35 → $29
Current: $12.61
Upside: +129.98%
Sep 11, 2025
Maintains: Outperform
Price Target: $15 → $33
Current: $0.12
Upside: +27,538.19%
Sep 5, 2025
Maintains: Outperform
Price Target: $12 → $15
Current: $2.63
Upside: +470.34%
Aug 15, 2025
Maintains: Outperform
Price Target: $19 → $20
Current: $5.34
Upside: +274.53%
Jun 2, 2025
Assumes: Outperform
Price Target: $61
Current: $31.05
Upside: +96.46%
Jun 2, 2025
Assumes: Outperform
Price Target: $15 → $7
Current: $4.10
Upside: +70.73%
May 29, 2025
Maintains: Outperform
Price Target: $6 → $3
Current: $1.61
Upside: +86.34%
May 16, 2025
Maintains: Outperform
Price Target: $14 → $4
Current: $0.89
Upside: +349.49%
May 13, 2025
Maintains: Outperform
Price Target: $155 → $90
Current: $12.84
Upside: +600.93%
May 13, 2025
Maintains: Outperform
Price Target: $15 → $9
Current: $1.49
Upside: +504.03%
Nov 15, 2024
Reiterates: Outperform
Price Target: $181
Current: $226.66
Upside: -20.14%
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $7.95
Upside: +138.99%
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $27.11
Upside: +6.97%
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $8.62
Upside: +143.62%
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $20.98
Upside: +967.68%
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $25.55
Upside: +123.09%
Oct 10, 2023
Maintains: Outperform
Price Target: $50 → $70
Current: $9.98
Upside: +601.40%
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $0.21
Upside: +4,661.90%
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $53.81
Upside: +30.10%